Stephens resumed coverage of Alpha Teknova with an Overweight rating and $8 price target. The company will benefit from growth in the biologics end market, the analyst tells investors in a research note. The firm believes Alpha continues to add to its clinical solutions customer base, which should drive revenue growth as demand ramps.
